MX2020010502A - Agentes farmacológicos para el tratamiento de enfermedades oculares. - Google Patents
Agentes farmacológicos para el tratamiento de enfermedades oculares.Info
- Publication number
- MX2020010502A MX2020010502A MX2020010502A MX2020010502A MX2020010502A MX 2020010502 A MX2020010502 A MX 2020010502A MX 2020010502 A MX2020010502 A MX 2020010502A MX 2020010502 A MX2020010502 A MX 2020010502A MX 2020010502 A MX2020010502 A MX 2020010502A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmacological agents
- ocular diseases
- treating ocular
- subject
- methods
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 title 1
- 108010071690 Prealbumin Proteins 0.000 abstract 2
- 102000009190 Transthyretin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010041 presbyopia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653249P | 2018-04-05 | 2018-04-05 | |
| US201862694729P | 2018-07-06 | 2018-07-06 | |
| PCT/US2019/026112 WO2019195761A2 (en) | 2018-04-05 | 2019-04-05 | Pharmacological agents for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010502A true MX2020010502A (es) | 2021-03-25 |
Family
ID=68101528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010502A MX2020010502A (es) | 2018-04-05 | 2019-04-05 | Agentes farmacológicos para el tratamiento de enfermedades oculares. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11872236B2 (https=) |
| JP (1) | JP7532259B2 (https=) |
| CN (1) | CN112601513B (https=) |
| BR (1) | BR112020020351A2 (https=) |
| MX (1) | MX2020010502A (https=) |
| WO (1) | WO2019195761A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120097859A (zh) * | 2019-02-19 | 2025-06-06 | 加利福尼亚大学董事会 | Nurr1受体调节剂 |
| EP3976017A4 (en) * | 2019-05-31 | 2023-06-14 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE |
| WO2021086834A1 (en) * | 2019-10-28 | 2021-05-06 | Kebotix, Inc. | Electronic control of transmittance of visible and near-infrared radiation |
| WO2022098847A1 (en) * | 2020-11-04 | 2022-05-12 | Corino Therapeutics, Inc. | Tolcapone analogs and methods of use |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| JP2023549533A (ja) * | 2020-11-13 | 2023-11-27 | プレックス ファーマスーティカルズ，インク | 眼の状態を処置するための薬理剤 |
| US20250019352A1 (en) * | 2021-06-29 | 2025-01-16 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating ophthalmic diseases |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
| WO2024123100A1 (ko) * | 2022-12-09 | 2024-06-13 | 경희대학교 산학협력단 | 신규 아밀로이드-베타 응집체 분해제와 이를 이용한 뇌 표적화 약물 전달 시스템 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| JPH1036257A (ja) * | 1996-05-22 | 1998-02-10 | Kikkoman Corp | メイラード反応阻害剤 |
| ID19540A (id) | 1997-01-22 | 1998-07-23 | Hoffmann La Roche | Metode pembuatan turunan-turunan benzofenon |
| JP2000256259A (ja) * | 1999-03-11 | 2000-09-19 | Nippon Zoki Pharmaceut Co Ltd | メイラード反応阻害剤 |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2011047412A1 (en) * | 2009-10-22 | 2011-04-28 | The Heart Research Institute Ltd | Tyrosine and l-dopa for reducing l-dopa incorporation into proteins |
| WO2011140333A1 (en) * | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| WO2014147464A2 (en) | 2013-03-20 | 2014-09-25 | Ra Chem Pharma Limited | Novel process for the preparation of tolcapone |
| WO2015095257A2 (en) * | 2013-12-18 | 2015-06-25 | Emory University | Managing visual dysfunction or loss of vision for diabetic subjects |
| RU2724190C2 (ru) | 2014-02-08 | 2020-06-23 | Дженентек, Инк. | Способы лечения болезни альцгеймера |
| KR20170048426A (ko) * | 2014-08-22 | 2017-05-08 | 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. | 시각 장애를 치료하기 위한 조성물 및 방법 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| CN116963727A (zh) | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| JP2023549533A (ja) | 2020-11-13 | 2023-11-27 | プレックス ファーマスーティカルズ，インク | 眼の状態を処置するための薬理剤 |
-
2019
- 2019-04-05 WO PCT/US2019/026112 patent/WO2019195761A2/en not_active Ceased
- 2019-04-05 US US17/045,430 patent/US11872236B2/en active Active
- 2019-04-05 JP JP2020554461A patent/JP7532259B2/ja active Active
- 2019-04-05 MX MX2020010502A patent/MX2020010502A/es unknown
- 2019-04-05 BR BR112020020351-3A patent/BR112020020351A2/pt unknown
- 2019-04-05 CN CN201980037118.2A patent/CN112601513B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3773438A2 (en) | 2021-02-17 |
| WO2019195761A2 (en) | 2019-10-10 |
| WO2019195761A3 (en) | 2020-07-23 |
| CN112601513A (zh) | 2021-04-02 |
| JP7532259B2 (ja) | 2024-08-13 |
| BR112020020351A2 (pt) | 2021-01-12 |
| CN112601513B (zh) | 2023-12-22 |
| US20210154213A1 (en) | 2021-05-27 |
| US11872236B2 (en) | 2024-01-16 |
| JP2021532059A (ja) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010502A (es) | Agentes farmacológicos para el tratamiento de enfermedades oculares. | |
| EP4491229A3 (en) | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| TW200633709A (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | |
| BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| JP2015025011A5 (https=) | ||
| WO2011053801A3 (en) | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye | |
| MX2015012653A (es) | Formulaciones oculares para suministro de farmaco al segmento porterior del ojo. | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| EA200800336A1 (ru) | Лечение состояний, связанных с присутствием макромолекулярных агрегатов, в частности глазных расстройств | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. | |
| HRP20190561T1 (hr) | Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom | |
| CA3167959A1 (en) | Prodrug for the treatment of disease and injury of oxidative stress | |
| MX2015016750A (es) | Composicion inmunogenica para uso en terapia. | |
| BRPI0407693A (pt) | uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| MX2021009777A (es) | Formulaciones inyectables de fenol y metodos de su uso. | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| MX2021015796A (es) | Composiciones y metodos para tratar enfermedades oculares. |